Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Canada / NCT07460674
Starting soon Observational

Serum FSH Levels During Controlled Ovarian Stimulation

NCT07460674 · tracked via the Priya Life Science Canada tracker
Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Phase
Observational
Started
2026-02-16
Last updated
2026-03-10

Condition(s) studied

Female Subjects Undergoing Controlled Ovarian Hyperstimulation

Study summary

Follicle-stimulating hormone (FSH) plays a central role in controlled ovarian stimulation (COS) during in vitro fertilization (IVF) cycles. While baseline FSH is commonly used to assess ovarian reserve, the clinical significance of dynamic FSH changes during stimulation remains unclear. Limited evidence suggests that serum FSH levels during COS may reflect ovarian response and could be associated with follicular development and treatment outcomes, yet FSH is not routinely monitored throughout stimulation protocols.

This prospective single-center cohort study aims to evaluate the dynamics of serum FSH levels during COS and to examine their association with ovarian response and IVF outcomes. Serum FSH, luteinizing hormone (LH) and estradiol (E2) will be measured at predefined time points during stimulation. Associations between FSH levels and oocyte yield, embryo development, and pregnancy outcomes will be analyzed to better understand the clinical relevance of FSH monitoring during IVF treatment.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
44 Years
Healthy volunteers
No
Inclusion Criteria: * Patients undergoing controlled ovarian stimulation * All stimulation protocols (agonist and antagonist). * All gonadotropin formulation (Gonal-F, Menopur, Rekovelle, Puregon). Exclusion Criteria: * Cancer fertility preservation patients . * Patients over age 44.

Primary outcome measure(s)

  • -Trigger day FSH levels — 60 months
    Serum Follicle-stimulating hormone (FSH) (mIU/mL) measured at the day of the trigger shot
  • Trigger day E2 levels — 60 months
    Serum Estradiol (E2) (pg/mL) levels measured at trigger shot day
  • Number of patients reaching trigger — 60 months
    The number of patients that received the trigger shot and proceeding to oocyte retrieval / The number pf patients canceled during the ovarian stimulation
  • Number of oocytes retrieved — 60 months
    The number of oocytes collected in the oocyte retrieval procedure
  • Number of transferable embryos — 60 months
    Number of embryos were transferred in the fresh cycle plus the number of frozen embryos

Trial sites (1)

FacilityCityRegionStatus
MUHC Reproductive Centre Montreal Quebec

More McGill University Health Centre/Research Institute of the McGill University Health Centre trials in Canada

Research Study for Single-Patient Treatment of Cree Leukoencephalopathy/Vanishing White Matter Disease Active, not recruiting
Radio-frequency (RF) Bladder Monitor Starting soon
Development of a Patient-Reported Outcome Measure to Assess Recovery After Abdominal Surgery Active, not recruiting
Acoustics as a Metric of Airway Pressure in Premature Infants Using Bubble Continuous Positive Airway Pressure Recruiting
Wireless MicroPremVitals Button Sensor in the NICU Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07460674 on ClinicalTrials.gov ↗ ← All trials in Canada